Скачать
The Impact of FDA Approval for Esketamine as Monotherapy in Treatment-Resistant Depression
Автор: HCPLive
Загружено: 2025-01-22
Просмотров: 733
Описание:
Johnson & Johnson announced on January 21, 2025, that the FDA approved esketamine (SPRAVATO) CIII nasal spray as a monotherapy for treatment-resistant depression.
HCPLive spoke with investigator Gregory Mattingly, MD, founding partner of St. Charles Psychiatric Associates following this news, discussing what this means for psychiatric care.
Read more about the approval here: https://www.hcplive.com/view/fda-appr...
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
